Bines JE, et al. - The objective herein was to investigate the efficacy of an oral human neonatal rotavirus vaccine (RV3-BB) for the prevention of rotavirus gastroenteritis. Findings reported that a vaccine efficacy of 75% was achieved in the neonatal-schedule group, 51% in the infant-schedule group, and 63% in the neonatal-schedule and infant-schedule groups combined (combined vaccine group). Therefore, RV3-BB was discovered to be efficacious in preventing severe rotavirus gastroenteritis when administered according to a neonatal or an infant schedule in Indonesia.